Adjuvant personalized multivalent neoantigen DNA vaccination for MGMT unmethylated glioblastoma: a phase 1 trial - Top-Institutions - MDSpire

Adjuvant personalized multivalent neoantigen DNA vaccination for MGMT unmethylated glioblastoma: a phase 1 trial

  • By

  • Elizabeth A. R. Garfinkle

  • Renzo Perales-Linares

  • Ryan C. Gimple

  • Alexandra J. Livingstone

  • Kaleigh F. Roberts

  • Omar H. Butt

  • S. Peter Goedegebuure

  • Michael D. McLellan

  • Gue Su Chang

  • Jasreet Hundal

  • Jian Yan

  • Jaye B. Navarro

  • Sophia A. Paxton

  • Srestha Chattopadhyay

  • Neil Cooch

  • Alfredo Perales-Puchalt

  • Konstantina Stavroulaki

  • Sarah Rochestie

  • Joann Peters

  • Beth Junker

  • Jian L. Campian

  • Milan G. Chheda

  • Michael R. Chicoine

  • Albert H. Kim

  • Jon T. Willie

  • Gregory J. Zipfel

  • Joshua L. Dowling

  • Christopher A. Miller

  • Obi L. Griffith

  • Malachi Griffith

  • William E. Gillanders

  • Katherine E. Miller

  • Elaine R. Mardis

  • Niranjan Y. Sardesai

  • Gavin P. Dunn

  • Tanner M. Johanns

  • May 12, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Oncology
  • #2

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Oncology
  • #3

    Columbia University
    Columbia University

    New York, NY

    Key Differentiators

    • Oncology
  • #4

    Herbert Irving Comprehensive Cancer Center
    Herbert Irving Comprehensive Cancer Center

    New York, NY

    Key Differentiators

    • Oncology
  • #5

    NewYork-Presbyterian
    NewYork-Presbyterian

    New York, NY

    Key Differentiators

    • Oncology

Original Source(s)

Related Content